Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,758 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Novartis Pharmaceuticals Clear all
Completed Phase 4 Interventional Results available

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

NCT00400400
View directory record Official record
Conditions
Renal Transplantation
Interventions
Enteric-coated mycophenolate sodium (EC-MPS), Mycophenolate mofetil, Placebo to mycophenolate sodium, Placebo to mycophenolate mofetil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
53
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2011 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 3 Interventional

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

NCT04557462
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
16
States / cities
Glendale, Arizona • San Diego, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT03333694
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)
Interventions
Cutaneous Cream application, Placebo Cutaneous Cream application
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Phoenix, Arizona • Fountain Valley, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

NCT01682083
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Placebos
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 1Phase 2 Interventional

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

NCT00354523
View directory record Official record
Conditions
Solid Tumor, Thyroid Cancer
Interventions
Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

NCT02367859
View directory record Official record
Conditions
Ameloblastoma, BRAF Gene Mutation
Interventions
Dabrafenib, Trametinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

Impact of Fingolimod Adherence on Outcomes

NCT05141669
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Fingolimod
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional Results available

Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT00939159
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
LBH589
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme

NCT01934361
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
buparlisib, carboplatin, lomustine, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Therapeutic Benefit of Tisagenlecleucel Compared to Existing Standard of Care in German Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT07103486
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

NCT07811869
View directory record Official record
Conditions
Chronic Pruritus of Unknown Origin
Interventions
Remibrutinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Tampa, Florida • Brighton, Massachusetts • Clarkston, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

NCT03905525
View directory record Official record
Conditions
Sjögren Syndrome
Interventions
CFZ533, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Immune Profiles in Multiple Sclerosis (MS) Patients and Healthy Volunteers Through Thoracic Duct Cannulation

NCT05162638
View directory record Official record
Conditions
Multiple Sclerosis, Healthy
Interventions
thoracic duct cannulation
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Withdrawn Phase 2 Interventional

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

NCT01964235
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
INC280, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

NCT01610284
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, BKM120, BKM120 matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
61
States / cities
Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional

Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316

NCT02878616
View directory record Official record
Conditions
Kidney Transplantation
Interventions
LFG316, IVIG
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Cardiac Safety of Indacaterol

NCT01263808
View directory record Official record
Conditions
Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2010 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460
View directory record Official record
Conditions
Dyslipidemia, Healthy Volunteers
Interventions
TAP311
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 21, 2026, 6:59 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT06308588
View directory record Official record
Conditions
Philadelphia Chromosome-Positive, Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Asciminib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
The Bronx, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 6:59 AM EDT
Completed No phase listed Observational

Identifying Diuretic Resistance in Patients With Acute Heart Failure

NCT02751242
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

NCT00846586
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
61
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional Results available

Study of Panobinostat in Patients With Neuroendocrine Tumors

NCT00985946
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
panobinostat (LBH589)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 21, 2026, 6:59 AM EDT
Completed Phase 4 Interventional

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

NCT00657891
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Creighton University
Other
Eligibility
16 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 21, 2026, 6:59 AM EDT
Terminated Phase 1 Interventional

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT03301896
View directory record Official record
Conditions
Solid Tumors
Interventions
LHC165, PDR001
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 21, 2026, 6:59 AM EDT